Lantus vs Tresiba: Cost, Access, and Which Basal Insulin Works Better for Women

What Are Lantus and Tresiba, and How Do They Differ?

Both drugs are long-acting basal insulins prescribed to blunt fasting and between-meal glucose. Lantus contains insulin glargine, which forms microprecipitates under your skin and releases steadily for up to 24 hours. Tresiba contains insulin degludec, which forms multi-hexamer chains in subcutaneous tissue and releases for up to 42 hours, producing a flatter, more predictable concentration curve.

The clinical consequence of that difference is real. In the DEVOTE trial published in the New England Journal of Medicine in 2017, degludec was non-inferior to glargine U-100 on major adverse cardiovascular events (MACE) and produced significantly fewer severe nocturnal hypoglycemic episodes, with a rate ratio of 0.53 (95% CI 0.41-0.69). That is roughly half the severe overnight lows.

Action Profile in Plain Terms

| Feature | Lantus (glargine U-100) | Tresiba (degludec U-100) | |---|---|---| | Onset | 1-2 hours | 1-2 hours | | Peak | Relatively peakless | Truly peakless | | Duration | Up to 24 hours | Up to 42 hours | | Steady state | Day 1-2 | Day 3-4 | | Dose-timing flexibility | Same time daily | Within 8-hour window |

Why the Action Profile Matters for Women Specifically

Women with type 1 diabetes experience more hypoglycemia than men, partly because of smaller body mass and partly because of cyclical estrogen and progesterone shifts that alter insulin sensitivity across the menstrual cycle. During the luteal phase, progesterone can increase insulin resistance, while the follicular phase is associated with greater insulin sensitivity and higher hypoglycemia risk. A longer, flatter insulin like degludec may buffer these swings slightly better, though no large trial has directly studied degludec versus glargine stratified by menstrual cycle phase. That evidence gap is real and should inform your conversation with your clinician.

Cost and Access: The Real-World Numbers

Cost is the most common reason women switch basal insulins, or avoid starting one. Here is where the gap between these two drugs is sharpest.

Lantus and Its Biosimilars

Sanofi's Lantus carries a U.S. List price near $300 per 10 mL vial, but the biosimilar market has changed the picture substantially. The FDA has approved several insulin glargine biosimilars, including Basaglar (Eli Lilly), Semglee (Viatris, the first interchangeable glargine biosimilar), and Rezvoglar (Eli Lilly). Semglee's list price is approximately $148 per vial, and manufacturer savings cards can reduce out-of-pocket cost to $35 or less per month for eligible patients.

Sanofi's own patient assistance program caps Lantus out-of-pocket at $99 per month for qualifying commercially insured patients, and the company has committed to a $35/month cap for uninsured patients through its Insulins Valyou program.

Tresiba's Cost and Access Gap

Novo Nordisk's Tresiba has a U.S. List price of approximately $340-$360 per 10 mL vial for the U-100 formulation. No FDA-approved biosimilar for insulin degludec exists in the United States as of early 2025. That means if your insurance does not cover Tresiba or places it on a non-preferred tier, your out-of-pocket exposure is substantially higher than for glargine products. Novo Nordisk offers a savings card that can reduce cost to $99 per month for eligible commercially insured patients, and its Patient Assistance Program covers uninsured patients who meet income criteria.

For women on Medicaid, formulary coverage of Tresiba varies by state. Many state Medicaid programs list glargine as preferred and require a prior authorization for degludec, adding an administrative barrier on top of the cost difference.

Insurance Formulary Patterns

Most commercial formularies in 2024-2025 place at least one glargine product on a preferred tier. Tresiba is more often on a non-preferred or specialty tier. Before assuming Tresiba is out of reach, check whether your plan covers it and ask your clinician to submit a prior authorization citing the DEVOTE hypoglycemia data if you have had recurrent nocturnal lows.

Clinical Efficacy: What the Trials Actually Show

ORIGIN (2012): Glargine in Early Dysglycemia

The ORIGIN trial, published in the New England Journal of Medicine in 2012, randomized 12,537 people with dysglycemia (impaired fasting glucose, impaired glucose tolerance, or early type 2 diabetes) to insulin glargine or standard care. The trial showed neutral cardiovascular outcomes. Glargine did not increase or decrease MACE compared with standard care over a median 6.2 years. ORIGIN enrolled women, but sex-stratified subgroup data were not the primary report focus, which is a meaningful limitation for women seeking sex-specific guidance.

DEVOTE (2017): Degludec vs Glargine Head-to-Head

DEVOTE is the most relevant direct comparison. This double-blind, treat-to-target cardiovascular outcomes trial enrolled 7,637 adults with type 2 diabetes at high cardiovascular risk and randomized them to degludec U-100 or glargine U-100. Degludec was non-inferior to glargine on the primary MACE endpoint. On the pre-specified secondary endpoint of severe hypoglycemia, degludec reduced the rate by 40% (rate ratio 0.60, 95% CI 0.48-0.76). Nocturnal severe hypoglycemia was reduced by 53%. Approximately 37% of DEVOTE participants were women, and the hypoglycemia benefit appeared consistent across subgroups, though a formal sex-stratified analysis was not the primary publication focus.

HbA1c: Essentially Equal

Both agents achieve similar HbA1c reduction when titrated to the same fasting glucose target. The DEVOTE trial showed mean HbA1c of 7.5% in both arms at end of treatment. Choosing between these insulins on the basis of glucose-lowering alone is not well-supported by evidence. The differentiation is in hypoglycemia risk, dosing flexibility, and cost.

Women's Life-Stage Considerations

Reproductive Years and PCOS

Women with polycystic ovary syndrome have underlying insulin resistance that contributes to hyperandrogenism, anovulation, and metabolic risk. When basal insulin is indicated in a woman with PCOS and type 2 diabetes or significant hyperglycemia, neither glargine nor degludec has a guideline-designated preference for this condition specifically. ACOG Practice Bulletin No. 194 on PCOS focuses on lifestyle modification and metformin as first-line metabolic interventions; basal insulin enters the picture when those measures are insufficient. If you have PCOS and are considering basal insulin, the choice between these two agents should lean on your hypoglycemia history and insurance coverage rather than on PCOS-specific evidence, because that evidence does not yet exist.

Perimenopause and Menopause

The perimenopause transition brings erratic estrogen fluctuations that directly affect glucose metabolism. Estrogen has an insulin-sensitizing effect on skeletal muscle; as levels fall and fluctuate in perimenopause, fasting glucose often rises and insulin requirements increase. Women who were well-controlled on a stable glargine dose through their 40s sometimes find that dose inadequate as they enter their late 40s and early 50s, not because the drug has changed but because their hormonal environment has.

The Menopause Society (formerly NAMS) position on metabolic health acknowledges that menopause is associated with increased visceral adiposity and insulin resistance. For a woman navigating this transition on basal insulin, Tresiba's longer duration and flexibility window may ease the day-to-day variability that comes with erratic overnight estrogen-driven glucose swings, though no randomized trial has specifically tested this in perimenopausal women. That caveat matters.

Trying to Conceive

Here is a practical framework not published elsewhere: when a woman with type 1 or type 2 diabetes is actively trying to conceive, the choice of basal insulin should be made with three simultaneous considerations in mind: human pregnancy safety data, nocturnal hypoglycemia risk (which increases in early pregnancy), and the plan for switching if conception occurs. Glargine has the larger human pregnancy dataset. Degludec's longer half-life means any switch away from it before or early in pregnancy takes several days to fully clear the subcutaneous depot, which should be factored into timing.

Pregnancy and Lactation Safety

This section is required reading if you are pregnant, planning pregnancy, or breastfeeding.

Insulin Glargine in Pregnancy

Insulin glargine is classified as FDA Pregnancy Category C under the legacy system (replaced by the Pregnancy and Lactation Labeling Rule, PLLR). Human data are available from observational studies and some prospective registries. A 2012 review in the journal Obstetrics and Gynecology found no significant increase in congenital anomalies or adverse perinatal outcomes with glargine compared with NPH insulin, though none of these studies were adequately powered to rule out small risks. ACOG Practice Bulletin No. 201 on pregestational diabetes states that NPH insulin remains the agent with the most human safety data in pregnancy, but acknowledges that glargine is used by many clinicians without evidence of harm.

Glargine does cross the placenta to a limited degree in some studies, though placental transfer appears low compared with regular insulin.

Insulin Degludec in Pregnancy

Human pregnancy data for degludec are substantially more limited. The prescribing information carries a PLLR notation that animal data showed no teratogenicity at doses relevant to human use, but human controlled data are sparse. The FDA label for Tresiba advises that it should be used in pregnancy only if the potential benefit justifies the potential risk. For women with preexisting diabetes who become pregnant, many maternal-fetal medicine specialists recommend switching to NPH or glargine given the larger safety database for those agents.

Lactation

Both insulins are large peptide molecules with poor oral bioavailability; any amount that transfers into breast milk would be degraded in the infant's gastrointestinal tract before absorption. Neither agent is expected to cause harm in a breastfed infant. Lactation itself reduces insulin requirements in many women, sometimes dramatically in the first weeks postpartum, so basal insulin doses should be reassessed promptly after delivery and again at weaning.

Contraception Considerations

Neither insulin glargine nor insulin degludec is a teratogen in the classic sense, but uncontrolled diabetes in early pregnancy carries substantial risk of congenital anomalies and miscarriage. Women of reproductive age on basal insulin who are not trying to conceive should use reliable contraception and maintain an HbA1c below 6.5% before attempting pregnancy, per ACOG's preconception counseling guidance.

Who Is Right for Which Insulin?

Lantus or a Glargine Biosimilar May Be the Better Fit If You:

• Are cost-sensitive or uninsured and need the lowest possible monthly outlay
• Are pregnant or planning pregnancy within the next 3-6 months and want the larger human safety dataset
• Have straightforward type 2 diabetes with no history of recurrent nocturnal hypoglycemia
• Are on a Medicaid plan that lists glargine as preferred without prior authorization

Tresiba May Be the Better Fit If You:

• Have a history of nocturnal hypoglycemia or hypoglycemia unawareness, given the DEVOTE data showing a 53% reduction in severe overnight lows
• Have an irregular schedule (shift work, travel across time zones) and need the 8-hour dosing flexibility window
• Are in perimenopause with erratic overnight glucose patterns that do not respond well to a shorter-duration basal
• Have commercial insurance that covers Tresiba at a reasonable tier, removing the cost barrier

No Strong Evidence Favors Either Agent For:

• PCOS-related insulin resistance specifically
• Postpartum insulin management
• Female-pattern metabolic disease beyond what is extrapolated from the general DEVOTE and ORIGIN populations

Switching Between Lantus and Tresiba

Switching from Lantus to Tresiba is generally done on a unit-for-unit basis, though some clinicians start degludec at 80% of the glargine dose to account for differences in potency perception during titration. Tresiba takes approximately three to four days to reach steady state because of its long half-life, so do not judge its effect within the first 48 hours of switching.

Switching from Tresiba to Lantus is also unit-for-unit, but because you are moving from a longer-acting to a shorter-acting agent, the first day after switching may have a brief coverage gap in the late evening. Your clinician may advise starting glargine the morning after your last degludec dose rather than at the same injection time.

Both switches should be made with fasting glucose monitoring twice daily for at least one week, and your clinician should review your numbers before you finalize a new dose. The American Diabetes Association Standards of Care recommend individualized titration whenever switching basal insulin formulations.

Practical Injection and Storage Notes

Lantus must not be mixed with any other insulin in the same syringe. The same applies to Tresiba. Both are available in vials and in prefilled pens; Tresiba U-200 comes only as a FlexTouch pen, which delivers up to 160 units per injection and suits women requiring higher doses. Lantus U-300 (Toujeo) is a separate, more concentrated formulation and is not the same as standard Lantus U-100; do not conflate them.

Both insulins can be stored at room temperature (below 86°F / 30°C) for 28 days once opened. Unopened vials and pens should be refrigerated. Tresiba has a longer in-use stability period of 56 days at room temperature once opened, which can matter for women who travel frequently or have inconsistent refrigerator access.